Quantcast

Latest Soft tissue sarcoma Stories

2011-06-08 08:00:00

EXTON, Pa., June 8, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designations to two of its investigational cancer drugs, MORAb-004 for the treatment of soft tissue sarcoma and MORAb-066 for the treatment of pancreatic cancer.

2011-05-27 16:00:00

INDIANAPOLIS, May 27, 2011 /PRNewswire/ -- In the press release, "Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas," issued May 19, 2011, by Eli Lilly and Company (NYSE: LLY), the following sentence has been amended to: The best overall responses were as follows: one partial response in the Ewing sarcoma tier (n=1); and no partial responses, but stable disease of 41 percent (n=9) in leiomyosarcoma; 35 percent (n=6) in synovial sarcoma; 28 percent (n=5) in Ewing family of...

2011-05-23 21:59:37

Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas.

2011-05-19 07:10:00

INDIANAPOLIS, May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

2011-02-28 13:46:00

SAN MARINO, Calif., Feb. 28, 2011 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that the U.S.

2011-02-15 19:29:02

Researchers at Oregon Health & Science University Doernbecher Children's Hospital have defined the cell of origin for a kind of cancer called sarcoma.

2010-12-14 00:01:36

Dr. Wittig to appear in the 6th edition of 'America's Top Doctors for Cancer' New York, NY (PRWEB) December 13, 2010 Dr. James C.

2010-06-01 12:25:00

SAN MARINO, Calif., June 1 /PRNewswire/ -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the results of the clinical trial entitled "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma" at the ASCO Annual Meeting on June 8, 2010.

2010-04-21 06:30:00

NEW YORK, April 21 /PRNewswire/ -- The Kristen Ann Carr Fund has awarded a grant to Jonathan Lewis, MD, PhD, Chief Executive Officer and Chief Medical Officer of ZIOPHARM Oncology, Inc., which will fund translational work at the Memorial Sloan-Kettering Cancer Center and the Albert Einstein College of Medicine in New York City, for the development of a novel treatment for pediatric sarcoma.